Chemotherapy-Related Toxicity, Nutritional Status and Quality of Life in Precachectic Oncologic Patients with, or without, High Protein Nutritional Support. A Prospective, Randomized Study

Monika Ziętarska, Joanna Krawczyk-Lipiec, Leszek Kraj, Renata Zaucha, Sylwia Małgorzewicz, Monika Ziętarska, Joanna Krawczyk-Lipiec, Leszek Kraj, Renata Zaucha, Sylwia Małgorzewicz

Abstract

Background: Cancer disease is usually associated with impaired nutritional status, which is one of the factors contributing to deterioration of the results of surgery, chemotherapy or radiotherapy.

Objectives: The aim of the study was to determine whether nutritional support with high protein (ONS) in adult oncologic patients in the first step of cancer cachexia-asymptomatic precachexia, has an influence on the toxicity of systemic therapy. However, secondary endpoints were established: to determine whether high protein ONS influences the nutritional status, the quality of life, and the performance status.

Materials and methods: A total of 114 persons aged 40-84 years old with colorectal cancer were examined. Based on the randomization, 47 patients were qualified to the interventional group (ONS group) and 48 to Control group. To evaluate the nutritional status NRS-2002 (Nutritional Risk Screening), SGA (Subjective Global Assessment), SCRINIO (SCReenIng the Nutritional status In Oncology) Working Group classification, VAS (Visual Analog Scale) for appetite was used. FAACT (Functional Assessment of Anorexia/Cachexia Therapy) questionnaire was used for assessment of the quality of life. The health status of patients was evaluated based on the Karnofsky Performance Scale. Anthropometric measurements were done.

Results: Severe complications of chemotherapy, which caused the end of treatment, a slight complication of the gastrointestinal tract such as diarrhea grade 2 according to ECOG (Eastern Cooperative Oncology Group) score regardless of the studied group, were observed. There were no statistical differences in the number and severity of the observed complications, i.e., neutropenia, leucopenia, thrombocytopenia, anemia, abdominal pain, nausea and vomiting, and diarrhea. During the follow-up the significant changes of SGA, VAS, albumin and prealbumin were observed between groups. In the ONS group an improvement in nutritional status was noticed (increased appetite VAS, p = 0.05; increased points in SGA, p = 0.015, and increased levels of albumin and prealbumin, p = 0.05). In Control group nutritional status was stable during observation. The performance status and quality of life were stable in both groups. No statistical differences between groups (ONS vs. Control) in the numbers for disqualification, resignation, delay in treatment, or dose reduction were observed.

Conclusions: Results of the study did not indicate that nutritional support in precachectic oncologic patients influenced the toxicity of systemic therapy. High protein nutritional support improved nutritional status assessed by SGA, VAS for appetite, albumin, and prealbumin. The performance status and quality of life were stable throughout the observation and were not changed under the supplementation.

Keywords: appetite; chemotherapy; colorectal cancer; nutritional status; oral nutritional supplementation; quality of life.

Conflict of interest statement

None of the authors has a conflict of interest.

Figures

Figure 1
Figure 1
The scheme of the study.
Figure 2
Figure 2
The changes of appetite (visual analog scale for appetite -VAS) during observation in both groups.
Figure 3
Figure 3
The changes of albumin, prealbumin and C-reactive protein (CRP) level during observation in ONS group (1—1st visit, 2—2nd, 3—3rd and 4th visit).

References

    1. Bozzetti F., Mariani L. Defining and classifying cancer cachexia: A proposal by the SCRINIO Working Group. JPEN J. Parenter. Enter. Nutr. 2009;33:361–367. doi: 10.1177/0148607108325076.
    1. Fearon K., Strasser F., Anker S.D., Bosaeus I., Bruera E., Fainsinger R.L., Jatoi A., Loprinzi C., MacDonald N., Mantovani G., et al. Definition and classification of cancer cachexia: An international consensus. Lancet Oncol. 2011;12:489–495. doi: 10.1016/S1470-2045(10)70218-7.
    1. Fearon K.C., Voss A.C., Hustead D.S., Cancer Cachexia Study Group Definition of cancer cachexia: Effect of weight loss, reduced food intake, and systemic inflammation on functional status and prognosis. Am. J. Clin. Nutr. 2006;83:1345–1350.
    1. Dewys W.D., Begg C., Lavin P.T., Band P.R., Bennett J.M., Bertino J.R., Cohen M.H., Douglass H.O., Jr., Engstrom P.F., Ezdinli E.Z., et al. Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group. Am. J. Med. 1980;69:491–497. doi: 10.1016/S0149-2918(05)80001-3.
    1. Stewart G.D., Skipworth R.J., Fearon K.C. Cancer cachexia and fatigue. Clin. Med. 2006;6:140–143. doi: 10.7861/clinmedicine.6-2-140.
    1. Fearon K.C., Barber M.D., Moses A.G. The cancer cachexia syndrome. Surg. Oncol. Clin. N. Am. 2001;10:109–126.
    1. Buskermolen S., Langius J.A., Kruizenga H.M., Ligthart-Melis G.C., Heymans M.W., Verheul H.M. Weight loss of 5% or more predicts loss of fat-free mass during palliative chemotherapy in patients with advanced cancer: A pilot study. Nutr. Cancer. 2012;64:826–832. doi: 10.1080/01635581.2012.690062.
    1. Pausch T., Hartwig W., Hinz U., Swolana T., Bundy B.D., Hackert T., Grenacher L., Büchler M.W., Werner J. Cachexia but not obesity worsens the postoperative outcome after pancreatoduodenectomy in pancreatic cancer. Surgery. 2012;152:81–88. doi: 10.1016/j.surg.2012.05.028.
    1. Lasheen W., Walsh D. The cancer anorexia-cachexia syndrome: Myth or reality? Support. Care Cancer. 2010;18:265–272. doi: 10.1007/s00520-009-0772-6.
    1. Capuano G., Gentile P.C., Bianciardi F., Tosti M., Palladino A., Di Palma M. Prevalence and influence of malnutrition on quality of life and performance status in patients with locally advanced head and neck cancer before treatment. Support. Care Cancer. 2010;18:433–437. doi: 10.1007/s00520-009-0681-8.
    1. MacDonald N. Terminology in cancer cachexia: Importance and status. Curr. Opin. Clin. Nutr. Metab. Care. 2012;15:220–225. doi: 10.1097/MCO.0b013e328352a895.
    1. Fearon K., Arends J., Baracos V. Understanding the mechanisms and treatment options in cancer cachexia. Nat. Rev. Clin. Oncol. 2013;10:90–99. doi: 10.1038/nrclinonc.2012.209.
    1. Arrieta O., Michel Ortega R.M., Villanueva-Rodríguez G., Serna-Thomé M.G., Flores-Estrada D., Diaz-Romero C., Rodríguez C.M., Martínez L., Sánchez-Lara K. Association of nutritional status and serum albumin levels with development of toxicity in patients with advanced non-small cell lung cancer treated with paclitaxel-cisplatin chemotherapy: A prospective study. BMC Cancer. 2010;10:50. doi: 10.1186/1471-2407-10-50.
    1. Lopes J.P., de Castro Cardoso Pereira P.M., dos Reis Baltazar Vicente A.F., Bernardo A., de Mesquita M.F. Nutritional status assessment in colorectal cancer patients. Nutr. Hosp. 2013;28:412–418.
    1. Caro M.M.M., Candela C.G., Rabaneda R.C., Nogueira T.L., Huerta A.G., Kohen V.L., Sanz M.V., Auñón P.Z., Pérez L.L., Sáenz P.R., et al. Nutritional risk evaluation and establishment of nutritional support in oncology patients according to the protocol of the Spanish Nutrition and Cancer Group. Nutr. Hosp. 2008;23:458–468.
    1. Krawczyk J., Korta T. Niedożywienie jako problem kliniczny u osób z rozpoznaną chorobą nowotworową leczonych systemowo. Postępy Żywienia Klinicznego. 2017;21:157–161.
    1. Bachmann J., Ketterer K., Marsch C., Fechtner K., Krakowski-Roosen H., Büchler M.W., Friess H., Martignoni M.E. Pancreatic cancer related cachexia: Influence on metabolism and correlation to weight loss and pulmonary function. BMC Cancer. 2009;9:255. doi: 10.1186/1471-2407-9-255.
    1. Hu W.H., Cajas-Monson L.C., Eisenstein S., Parry L., Cosman B., Ramamoorthy S. Preoperative malnutrition assessments as predictors of postoperative mortality and morbidity in colorectal cancer: An analysis of ACS-NSQIP. Nutr. J. 2015;14:91. doi: 10.1186/s12937-015-0081-5.
    1. Borda F., Borda A., Jiménez J., Zozaya J.M., Prieto C., Gómez M., Urman J., Ibáñez B. Predictive value of pre-treatment hypoalbuminemia in prognosis of resected colorectal cancer. Gastroenterol. Hepatol. 2014;37:289–295. doi: 10.1016/j.gastrohep.2013.12.007.
    1. Ihara K., Yamaguchi S., Shida Y., Ogata H., Domeki Y., Okamoto K., Nakajima M., Sasaki K., Tsuchioka T., Kato H. Poor nutritional status before and during chemotherapy leads to worse prognosis in unresectable advanced or recurrent colorectal cancer. Int. Surg. 2015 doi: 10.9738/INTSURG-D-15-00079.1.

Source: PubMed

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

3
S'abonner